All In Biotech

Drug Trial Radar · NCT07902830

A Study to Investigate the Safety and Tolerability of Granulocyte-colony Stimulating Factor (G-CSF) Dosage Reduction in Mavorixafor-treated Participants With Acquired Primary Autoimmune and Idiopathic Chronic Neutropenia Disorders

A Phase 2b, Single-arm, Open-label, Multicenter Study to Evaluate the Safety and Tolerability of G-CSF Dosage Reduction With Mavorixafor in Participants With Acquired Primary Autoimmune and Idiopathic Chronic Neutropenia Disorders

Last checked: Nov 19, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Dec 2026

Primary completion

Jan 30, 2029

Study completion Jan 30, 2029

Sponsor

Lead sponsor
X4 PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Oct 29, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and tolerability of G-CSF dosage reduction with mavorixafor in participants with autoimmune neutropenia (AIN) and chronic idiopathic neutropenia (CIN) disorders as assessed by the ability to safely reduce G-CSF dosage with mavorixafor treatment while maintaining clinically acceptable absolute neutrophil count (ANC) levels.

Conditions

  • Acquired Primary Autoimmune and Idiopathic Chronic Neutropenia Disorders
  • Chronic Neutropenia
  • Autoimmune Neutropenia
  • Chronic Idiopathic Neutropenia

Interventions

  • MavorixaforDrug

    Mavorixafor will be administered per schedule specified in the arm description.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs)Time frame: Up to Week 56
  2. Percent Change in Average Daily G-CSF DosageTime frame: Week 12 through Week 28 or 32
  3. Percentage of Participants Achieving G-CSF CessationTime frame: Week 28 or 32
  4. Percentage of Participants Achieving G-CSF Dosage Reduction ≥75%Time frame: Week 28 or 32

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.